Dipak Panigrahy, MD

Dr. Panigrahy is the world’s leading expert in Resolvin pharmacology in cancer. He is an Assistant Professor of Pathology at Beth Israel Deaconess Medical Center (BIDMC), a teaching hospital affiliated with Harvard Medical School. His laboratory, which is located in the Center for Vascular Biology Research at BIDMC, has deep expertise in multiple animal models of cancer including pancreatic cancer. From 1996 to 2008, Dr. Panigrahy led angiogenesis and cancer animal modeling in the Judah Folkman laboratory. The Panigrahy Laboratory has won 50+ awards for its studies on lipid autacoids in cancer. Dr. Panigrahy was awarded the 2015 ASIP Cotran Early Investigator Award and a Young Investigator Award in 2015 at the 14th International Conference on Bioactive Lipids in Cancer, Inflammation, and Related Diseases (Budapest, Hungary). Dr. Panigrahy’s seminal research regarding apoptosis in cancer and tumor dormancy escape provides the mechanistic foundation for our understanding of Resolvin pharmacology in cancer. In collaboration with the Serhan Laboratory, Dr. Panigrahy conducted the initial proof-of-concept studies for RvE1 in cancer.